Stoke Therapeutics’ (STOK) Buy Rating Reiterated at Cowen

Cowen reaffirmed their buy rating on shares of Stoke Therapeutics (NASDAQ:STOK) in a report issued on Thursday, AnalystRatings.com reports.

A number of other analysts also recently weighed in on the stock. Canaccord Genuity assumed coverage on shares of Stoke Therapeutics in a report on Monday, July 15th. They set a buy rating and a $44.00 price target for the company. Credit Suisse Group assumed coverage on shares of Stoke Therapeutics in a report on Monday, July 15th. They set an outperform rating and a $35.00 price target for the company. Finally, JPMorgan Chase & Co. assumed coverage on shares of Stoke Therapeutics in a report on Monday, July 15th. They set an overweight rating and a $34.00 price target for the company.

Shares of Stoke Therapeutics stock opened at $30.87 on Thursday. The stock’s 50 day moving average price is $26.63. Stoke Therapeutics has a 1-year low of $22.01 and a 1-year high of $31.97.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($1.54) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.96) by ($0.58). On average, research analysts forecast that Stoke Therapeutics will post -1.69 earnings per share for the current year.

In related news, major shareholder Rtw Investments, Lp acquired 555,556 shares of the stock in a transaction that occurred on Wednesday, June 19th. The stock was acquired at an average cost of $18.00 per share, for a total transaction of $10,000,008.00. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, major shareholder Apple Tree Partners Iv, L.P. acquired 1,388,889 shares of the stock in a transaction that occurred on Friday, June 21st. The shares were bought at an average price of $18.00 per share, with a total value of $25,000,002.00. The disclosure for this purchase can be found here.

A number of hedge funds have recently added to or reduced their stakes in the stock. Platinum Investment Management Ltd. acquired a new position in Stoke Therapeutics during the 2nd quarter worth approximately $29,000. Victory Capital Management Inc. acquired a new position in Stoke Therapeutics during the 2nd quarter worth approximately $73,000. Ladenburg Thalmann Financial Services Inc. acquired a new position in Stoke Therapeutics during the 2nd quarter worth approximately $88,000. Morgan Stanley acquired a new position in Stoke Therapeutics during the 2nd quarter worth approximately $104,000. Finally, KCL Capital L.P. acquired a new position in Stoke Therapeutics during the 2nd quarter worth approximately $292,000. Institutional investors and hedge funds own 1.42% of the company’s stock.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001, to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc has a partnership with Invitae Corporation to offer epilepsy panel testing.

Read More: Hold Rating

Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.